Table 5.
• General risk assessment based on |
- exposure (e. g. high exposure in drug-drug interaction trials, supra-therapeutic exposure in thorough QT trials) |
- frequency of relevant adverse events |
• Protocol to define stopping rules and decision making process for individual subjects, cohorts, and entire trial |